deltatrials
Active Not Recruiting PHASE3 INTERVENTIONAL 2-arm NCT04628494

A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) (EPCORE DLBCL-1)

A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

Sponsor: AbbVie

Conditions Diffuse Large B-cell Lymphoma
Interventions Epcoritamab Investigator's Choice Chemotherapy
Updated 41 times since 2020 Last updated: Mar 2, 2026 Started: Jan 13, 2021 Primary completion: Oct 13, 2025 Completion: Apr 30, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Diffuse Large B-cell Lymphoma, this trial is ongoing. The trial is conducted by AbbVie and has accumulated 41 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Sep 2021 · 7 months · monthly snapshot~Sep 2021 – ~Dec 2021 · 3 months · monthly snapshot~Dec 2021 – ~Jun 2022 · 6 months · monthly snapshot~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshot~Sep 2022 – ~Dec 2022 · 3 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Feb 2024 · 5 months · monthly snapshot~Feb 2024 – ~Mar 2024 · 29 days · monthly snapshot~Mar 2024 – ~Apr 2024 · 31 days · monthly snapshot~Apr 2024 – ~May 2024 · 30 days · monthly snapshot~May 2024 – ~Jun 2024 · 31 days · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Nov 2024 · 31 days · monthly snapshot~Nov 2024 – ~Dec 2024 · 30 days · monthly snapshot~Dec 2024 – ~Feb 2025 · 2 months · monthly snapshot~Feb 2025 – ~Mar 2025 · 28 days · monthly snapshot~Mar 2025 – ~Apr 2025 · 31 days · monthly snapshot~Apr 2025 – ~May 2025 · 30 days · monthly snapshot~May 2025 – ~Jun 2025 · 31 days · monthly snapshot~Jun 2025 – ~Aug 2025 · 2 months · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – ~Nov 2025 · 31 days · monthly snapshot~Nov 2025 – ~Dec 2025 · 30 days · monthly snapshot~Dec 2025 – ~Jan 2026 · 31 days · monthly snapshot~Jan 2026 – ~Feb 2026 · 31 days · monthly snapshot~Feb 2026 – ~Mar 2026 · 28 days · monthly snapshot~Mar 2026 – present · 6 months · monthly snapshot

Change History

41 versions recorded

  1. Mar 2026 — Present [monthly]

    Active Not Recruiting PHASE3

  2. Feb 2026 — Mar 2026 [monthly]

    Active Not Recruiting PHASE3

  3. Jan 2026 — Feb 2026 [monthly]

    Active Not Recruiting PHASE3

  4. Dec 2025 — Jan 2026 [monthly]

    Active Not Recruiting PHASE3

  5. Nov 2025 — Dec 2025 [monthly]

    Active Not Recruiting PHASE3

▶ Show 36 earlier versions

  1. Oct 2025 — Nov 2025 [monthly]

    Active Not Recruiting PHASE3

  2. Sep 2025 — Oct 2025 [monthly]

    Active Not Recruiting PHASE3

  3. Aug 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE3

  4. Jun 2025 — Aug 2025 [monthly]

    Active Not Recruiting PHASE3

  5. May 2025 — Jun 2025 [monthly]

    Active Not Recruiting PHASE3

  6. Apr 2025 — May 2025 [monthly]

    Active Not Recruiting PHASE3

  7. Mar 2025 — Apr 2025 [monthly]

    Active Not Recruiting PHASE3

  8. Feb 2025 — Mar 2025 [monthly]

    Active Not Recruiting PHASE3

  9. Dec 2024 — Feb 2025 [monthly]

    Active Not Recruiting PHASE3

  10. Nov 2024 — Dec 2024 [monthly]

    Active Not Recruiting PHASE3

  11. Oct 2024 — Nov 2024 [monthly]

    Active Not Recruiting PHASE3

  12. Sep 2024 — Oct 2024 [monthly]

    Active Not Recruiting PHASE3

  13. Aug 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE3

  14. Jul 2024 — Aug 2024 [monthly]

    Active Not Recruiting PHASE3

  15. Jun 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE3

  16. May 2024 — Jun 2024 [monthly]

    Active Not Recruiting PHASE3

  17. Apr 2024 — May 2024 [monthly]

    Active Not Recruiting PHASE3

  18. Mar 2024 — Apr 2024 [monthly]

    Active Not Recruiting PHASE3

  19. Feb 2024 — Mar 2024 [monthly]

    Active Not Recruiting PHASE3

  20. Sep 2023 — Feb 2024 [monthly]

    Active Not Recruiting PHASE3

  21. Aug 2023 — Sep 2023 [monthly]

    Active Not Recruiting PHASE3

  22. Jul 2023 — Aug 2023 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  23. Jun 2023 — Jul 2023 [monthly]

    Recruiting PHASE3

  24. May 2023 — Jun 2023 [monthly]

    Recruiting PHASE3

  25. Apr 2023 — May 2023 [monthly]

    Recruiting PHASE3

  26. Mar 2023 — Apr 2023 [monthly]

    Recruiting PHASE3

  27. Feb 2023 — Mar 2023 [monthly]

    Recruiting PHASE3

  28. Jan 2023 — Feb 2023 [monthly]

    Recruiting PHASE3

  29. Dec 2022 — Jan 2023 [monthly]

    Recruiting PHASE3

  30. Sep 2022 — Dec 2022 [monthly]

    Recruiting PHASE3

  31. Jun 2022 — Sep 2022 [monthly]

    Recruiting PHASE3

  32. Dec 2021 — Jun 2022 [monthly]

    Recruiting PHASE3

  33. Sep 2021 — Dec 2021 [monthly]

    Recruiting PHASE3

  34. Feb 2021 — Sep 2021 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  35. Jan 2021 — Feb 2021 [monthly]

    Not Yet Recruiting PHASE3

  36. Dec 2020 — Jan 2021 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AbbVie
  • Genmab
Data source: Genmab

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalborg, Denmark , Aarhus, Denmark , Amiens, France , Ankara, Turkey (Türkiye) , Antwerp, Belgium , Arnhem, Netherlands , Badalona, Spain , Barcelona, Spain , Bari, Italy , Bayonne, France and 139 more locations